Comparison of paclitaxel and docetaxel activity on human ovarian carcinoma xenografts

The antitumour activity of paclitaxel (NSC 125973) and docetaxel (RP 56976, NSC 628503) was evaluated and compared against human ovarian carcinoma (HOC) xenografts in nude mice. Paclitaxel and docetaxel were given intravenously (i.v.) at a dose range of 16.6–34.5 mg/kg, once every 4 days for three consecutive doses to nude mice with HOC xenografts, transplanted subcutaneously (s.c.) (HOC18 and HOC22-S) or intraperitoneally (i.p.) (HOC8 and HOC22). Paclitaxel and docetaxel, at the highest dosage, induced complete tumour regression in 80–100% and 67% of mice bearing HOC22-S and HOC18 s.c., respectively. Both drugs cured 100% of mice bearing early stage HOC22 tumour in the peritoneal cavity, while treatment at an advanced stage significantly increased the survival time of all the mice. Both induced a 57% cure rate in mice bearing HOC8 in the peritoneal cavity. Paclitaxel and docetaxel were more effective than cisplatin (4 mg/kg, same dosing regime as above) used as a reference compound. These findings indicate that paclitaxel and docetaxel were highly active on four HOC xenograft models. No significant difference between them was detected in ovarian cancer xenografts.